EMBrACe – Patient empowerment through competence: reaching for health beyond the absence of cancer.
Not Applicable
Recruiting
- Conditions
- C81Hodgkin lymphoma
- Registration Number
- DRKS00032098
- Lead Sponsor
- niversitätsklinikum Köln
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Histologically verified initial diagnosis of Hodgkin lymphoma
The patient is therapy-naïve with regard to HL
Written declaration of consent to participate in the study available
The patient agrees that the personal data will be made available to the study in compliance with data protection.
Exclusion Criteria
• Inability to communicate in German
• lack of compliance
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Subjective level of information measured with the total score of the EORTC QLQ-INFO25 questionnaire one year after the end of HL therapy
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie patient empowerment strategies in DRKS00032098 for Hodgkin lymphoma?
How does EMBrACe intervention compare to standard-of-care in C81 Hodgkin lymphoma patient outcomes?
Are there specific biomarkers associated with successful patient empowerment in C81 Hodgkin lymphoma?
What adverse events are reported in patient empowerment programs for C81 Hodgkin lymphoma?
What combination approaches or competitor drugs exist for patient-centered care in C81 Hodgkin lymphoma?